The U.S. FTC files a complaint against five pharmaceutical companies for pay-for-delay settlements (AbbVie)

On September 8, 2014, the Federal Trade Commission (FTC) filed a federal antitrust complaint in the United States District Court for the Eastern District of Pennsylvania against defendants AbbVie, Abbott Laboratories, Unimed Pharmaceuticals, Besins Healthcare and Teva Pharmaceuticals alleging violations of Section 5 of the FTC Act, 15 U.S.C. § 45(a), for entering into an agreement to maintain a monopoly over and restrain generic competition to AndroGel, a testosterone replacement therapy product. The complaint claims that the defendants entered into an illegal “reverse-payment” settlement, but additionally — and in a departure from previous cases the FTC has filed — that AbbVie, Abbott, Unimed and Besins (the Abbott Defendants) filed sham patent infringement lawsuits against potential

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

  • Skadden, Arps, Slate, Meagher & Flom (New York)
  • Skadden, Arps, Slate, Meagher & Flom (Washington DC)
  • Skadden, Arps, Slate, Meagher & Flom (New York)

Citation

Paul M.  Eckles, Steven C. Sunshine, Karen M. Lent, The U.S. FTC files a complaint against five pharmaceutical companies for pay-for-delay settlements (AbbVie), 8 septembre 2014, e-Competitions September 2014, Art. N° 69298

Visites 545

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues